[go: up one dir, main page]

WO2009113810A3 - Pharmaceutical composition, use thereof, and method for the treatment or prevention of allergic and autoimmune diseases - Google Patents

Pharmaceutical composition, use thereof, and method for the treatment or prevention of allergic and autoimmune diseases Download PDF

Info

Publication number
WO2009113810A3
WO2009113810A3 PCT/KR2009/001217 KR2009001217W WO2009113810A3 WO 2009113810 A3 WO2009113810 A3 WO 2009113810A3 KR 2009001217 W KR2009001217 W KR 2009001217W WO 2009113810 A3 WO2009113810 A3 WO 2009113810A3
Authority
WO
WIPO (PCT)
Prior art keywords
allergic
autoimmune diseases
pharmaceutical composition
preventing
provides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2009/001217
Other languages
French (fr)
Korean (ko)
Other versions
WO2009113810A2 (en
Inventor
전숙영
남동호
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020090019625A external-priority patent/KR100946747B1/en
Application filed by Individual filed Critical Individual
Publication of WO2009113810A2 publication Critical patent/WO2009113810A2/en
Publication of WO2009113810A3 publication Critical patent/WO2009113810A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention provides a pharmaceutical composition for preventing or treating allergic or autoimmune diseases, which contains immunoglobulin, as an active ingredient, isolated from the blood of a patient who is suffering from an allergic or autoimmune disease. In addition, the disclosed invention provides another pharmaceutical composition for preventing or treating allergic or autoimmune diseases, which contains immunoglobulin isolated from the blood of another patient who is suffering from an allergic or autoimmune disease as an active ingredient. The present invention also provides a manufacturing method and a medicinal and pharmaceutical use of the composition of a medicine for preventing or treating allergic or autoimmune diseases. Also, the disclosed invention provides a method for preventing and treating allergic or autoimmune diseases, which includes administering the pharmaceutical composition to mammals. By administering the disclosed pharmaceutical composition to mammals, allergic or autoimmune diseases, which are hard to control with a current standard drug treatment method, can be treated. Therefore, through the pharmaceutical composition, the use thereof for preventing or treating allergic or autoimmune disease, and the prevention and treatment method using the same, allergic or autoimmune diseases whose symptoms are not easily treated with current standard drug treatment methods can be more effectively treated.
PCT/KR2009/001217 2008-03-11 2009-03-11 Pharmaceutical composition, use thereof, and method for the treatment or prevention of allergic and autoimmune diseases Ceased WO2009113810A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2008-0022288 2008-03-11
KR20080022288 2008-03-11
KR1020090019625A KR100946747B1 (en) 2008-03-11 2009-03-09 Pharmaceutical compositions for the prevention or treatment of allergic diseases and autoimmune diseases, uses thereof and methods of preventing or treating allergic diseases and autoimmune diseases
KR10-2009-0019625 2009-03-09

Publications (2)

Publication Number Publication Date
WO2009113810A2 WO2009113810A2 (en) 2009-09-17
WO2009113810A3 true WO2009113810A3 (en) 2009-11-26

Family

ID=41065670

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/001217 Ceased WO2009113810A2 (en) 2008-03-11 2009-03-11 Pharmaceutical composition, use thereof, and method for the treatment or prevention of allergic and autoimmune diseases

Country Status (1)

Country Link
WO (1) WO2009113810A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112638442B (en) * 2018-06-29 2024-10-29 爱德芳世株式会社 Percutaneous terminal

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5653623A (en) * 1979-10-09 1981-05-13 Mochida Pharmaceut Co Ltd Remedy for allergic disease
JPH07133229A (en) * 1993-11-09 1995-05-23 Fumakilla Ltd Mite allergen
KR100756974B1 (en) * 2006-03-16 2007-09-07 전숙영 Pharmaceutical compositions and kits for the treatment of allergic diseases and chronic inflammatory diseases
KR20070095229A (en) * 2006-03-20 2007-09-28 전숙영 Pharmaceutical compositions for the prevention or treatment of allergic diseases, uses thereof and methods for preventing or treating allergic diseases
KR20070121217A (en) * 2006-06-21 2007-12-27 남상윤 Cell therapies for the treatment of autoimmune diseases caused by autologous cell destruction and methods of manufacturing the same

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5653623A (en) * 1979-10-09 1981-05-13 Mochida Pharmaceut Co Ltd Remedy for allergic disease
JPH07133229A (en) * 1993-11-09 1995-05-23 Fumakilla Ltd Mite allergen
KR100756974B1 (en) * 2006-03-16 2007-09-07 전숙영 Pharmaceutical compositions and kits for the treatment of allergic diseases and chronic inflammatory diseases
KR20070095229A (en) * 2006-03-20 2007-09-28 전숙영 Pharmaceutical compositions for the prevention or treatment of allergic diseases, uses thereof and methods for preventing or treating allergic diseases
KR20070121217A (en) * 2006-06-21 2007-12-27 남상윤 Cell therapies for the treatment of autoimmune diseases caused by autologous cell destruction and methods of manufacturing the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PITTLER, M. H. ET AL.: "Randomized, double-blind, placebo-controlled trial of autologous blood therapy for atopic dermatitis", BR. J. DERMATOL., vol. 148, no. 2, February 2003 (2003-02-01), pages 307 - 313 *
STAUBACH, P. ET AL.: "Autologous whole blood injections to patients with chronic urticaria and a positive autologous serum skin test: a placebo-controlled trial", DERMATOLOGY, vol. 212, no. 2, 2006, pages 150 - 159 *

Also Published As

Publication number Publication date
WO2009113810A2 (en) 2009-09-17

Similar Documents

Publication Publication Date Title
HK1199726A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
PH12012501480A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
AU2012286851A8 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2007136518A3 (en) Treatment of autoimmune disorders
EA201270144A1 (en) COMBINED THERAPY FOR TREATMENT OF DIABETES
MY166890A (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2006037031A3 (en) Formulations and methods for treatment of inflammatory diseases
EA201270221A1 (en) TREATMENT OF CROWN DISEASE WITH LACQUINIMODE
MY157564A (en) Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
HK1202776A1 (en) Use of laquinimod for treating crohn's disease patients who failed first-line anti-tnf therapy
MX2012000275A (en) Acid pump antagonist for treatment of diseases associated with abnormal gastrointestinal movement.
EA201492010A1 (en) APPLICATION OF HIGH DOSE OF LACHINIMODE FOR TREATMENT OF MULTIPLE SCLEROSIS
MX2008013635A (en) Use of therapeutic human albumin for the preparation of a drug for the treatment of patients suffering from cognitive disorders.
WO2006098603A3 (en) Composition comprising isoorientin for suppressing histamine
WO2010151565A3 (en) Combination therapies for the treatment of obesity
MX2012001708A (en) Humanized anti-amyloid-î oligomer antibody.
WO2009003694A3 (en) Method for treating diseases related to mitochondrial dysfunction
WO2007096396A3 (en) Methods for treating autoimmune or demyelinating diseases
UA99094C2 (en) Method for the treatment of patients with autoantibody positive disease
JP2016505050A5 (en)
WO2007081486A3 (en) Oral administration of defensins to treat intestinal diseases
WO2007056301A3 (en) Antibody therapy for treatment of diseases associated with gluten intolerance
WO2009113810A3 (en) Pharmaceutical composition, use thereof, and method for the treatment or prevention of allergic and autoimmune diseases
UA109359C2 (en) TREATMENT OF SKIN DISEASES AND STATES
WO2007070385A3 (en) Treatment of multiple sclerosis using interferon-tau

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09720487

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09720487

Country of ref document: EP

Kind code of ref document: A2